David Melnychuk

2.0k total citations
22 papers, 849 citations indexed

About

David Melnychuk is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Melnychuk has authored 22 papers receiving a total of 849 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Melnychuk's work include Cancer Treatment and Pharmacology (4 papers), Vitamin C and Antioxidants Research (3 papers) and Therapeutic Uses of Natural Elements (3 papers). David Melnychuk is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Vitamin C and Antioxidants Research (3 papers) and Therapeutic Uses of Natural Elements (3 papers). David Melnychuk collaborates with scholars based in Canada, United States and Australia. David Melnychuk's co-authors include Wilson H. Miller, L. John Hoffer, Line Robitaille, Mark Levine, Caroline Rousseau, Sarit Assouline, Kristopher A. Rosadiuk, Sebastian J. Padayatty, Lucien Abenhaim and Janet Dancey and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

David Melnychuk

22 papers receiving 808 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Melnychuk Canada 12 352 270 210 125 125 22 849
Anthe S. Zandvliet Netherlands 18 111 0.3× 215 0.8× 65 0.3× 230 1.8× 70 0.6× 39 976
Mani Menon United States 15 58 0.2× 125 0.5× 87 0.4× 338 2.7× 94 0.8× 39 975
Rayko Evstatiev Austria 18 178 0.5× 123 0.5× 68 0.3× 243 1.9× 76 0.6× 33 1.4k
I Iacona Italy 17 137 0.4× 161 0.6× 238 1.1× 173 1.4× 21 0.2× 27 970
C. Astre France 18 197 0.6× 250 0.9× 67 0.3× 119 1.0× 30 0.2× 49 792
Henri Michel France 13 102 0.3× 158 0.6× 34 0.2× 214 1.7× 33 0.3× 40 1.1k
Harold D. Frankl United States 16 215 0.6× 334 1.2× 347 1.7× 333 2.7× 214 1.7× 23 1.6k
Reza Khosravan United States 18 23 0.1× 199 0.7× 97 0.5× 314 2.5× 67 0.5× 36 1.2k
Thomas U. Ahearn United States 18 94 0.3× 255 0.9× 212 1.0× 292 2.3× 354 2.8× 43 1.1k
Preben Jakobsen Denmark 17 61 0.2× 193 0.7× 135 0.6× 220 1.8× 23 0.2× 36 815

Countries citing papers authored by David Melnychuk

Since Specialization
Citations

This map shows the geographic impact of David Melnychuk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Melnychuk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Melnychuk more than expected).

Fields of papers citing papers by David Melnychuk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Melnychuk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Melnychuk. The network helps show where David Melnychuk may publish in the future.

Co-authorship network of co-authors of David Melnychuk

This figure shows the co-authorship network connecting the top 25 collaborators of David Melnychuk. A scholar is included among the top collaborators of David Melnychuk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Melnychuk. David Melnychuk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morin, Vincent, et al.. (2021). The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature. Cancer Reports. 5(7). e1531–e1531. 6 indexed citations
2.
Hoffer, L. John, Line Robitaille, Robert Zakarian, et al.. (2015). High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial. PLoS ONE. 10(4). e0120228–e0120228. 88 indexed citations
3.
Rho, Young Soo, Aline Mamo, Marine Gilabert, et al.. (2015). Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 15(2). 135–140. 27 indexed citations
4.
Chan, Karen K. L., T. Vuong, Petr Kavan, et al.. (2012). Does the Compliance to Adjuvant Chemotherapy Depend on Neoadjuvant Radiation Therapy Modality?. Annals of Oncology. 23. ix200–ix200. 1 indexed citations
5.
Robitaille, Line, Orval Mamer, Wilson H. Miller, et al.. (2009). Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism. 58(2). 263–269. 49 indexed citations
6.
Hoffer, L. John, Mark Levine, Sarit Assouline, et al.. (2008). Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Annals of Oncology. 19(11). 1969–1974. 285 indexed citations
7.
Kavan, Petr, David Melnychuk, Adrian Langleben, et al.. (2007). Phase I study of ECO-4601, a novel Ras pathway inhibitor. Journal of Clinical Oncology. 25(18_suppl). 14128–14128. 5 indexed citations
8.
Talbot, Denis, Vladimir Moiseyenko, Simon Van Belle, et al.. (2002). Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. British Journal of Cancer. 86(9). 1367–1372. 157 indexed citations
9.
Zee, Benny, David Melnychuk, Janet Dancey, & Elizabeth A. Eisenhauer. (1999). MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION. Journal of Biopharmaceutical Statistics. 9(2). 351–363. 54 indexed citations
10.
Melnychuk, David, et al.. (1997). Determinants of Initiation and Suboptimal Use of Anti‐ulcer Medication: A Study of the Quebec Older Population. Journal of the American Geriatrics Society. 45(7). 853–856. 3 indexed citations
11.
Alpert, Lesley, Donald A. Berry, David Melnychuk, et al.. (1997). Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer.. PubMed. 3(5). 661–7. 22 indexed citations
12.
Nabholtz, J.-M., W.R. Bezwoda, David Melnychuk, et al.. (1997). Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.. PubMed. 11(8 Suppl 8). 25–30. 31 indexed citations
13.
Wang, Tiantian, et al.. (1996). Modulation of glutathione by a cysteine pro-drug enhances in vivo tumor response.. Journal of Pharmacology and Experimental Therapeutics. 276(3). 1169–1173. 19 indexed citations
14.
Zee, Benny, David Melnychuk, Janet Dancey, & Elizabeth A. Eisenhauer. (1996). A80 Design of Phase II clinical trials incorporating response and early progression. Controlled Clinical Trials. 17(2). S85–S85. 5 indexed citations
15.
Bégin, Louis R., Walter Schürch, Judith Lacoste, John Hiscott, & David Melnychuk. (1994). Glycogen-Rich Clear Cell Rhabdomyosarcoma of the Mediastinum. The American Journal of Surgical Pathology. 18(3). 302–308. 13 indexed citations
16.
Melnychuk, David & Lucien Abenhaim. (1992). Pharmacoepidemiology—an introduction. Journal of Clinical Epidemiology. 45(4). 437–437. 23 indexed citations
17.
Melnychuk, David, et al.. (1992). Revaccination of children during school-based measles outbreaks: potential impact of a new policy recommendation.. PubMed. 146(6). 929–36. 7 indexed citations
18.
Melnychuk, David. (1990). Pertussis outbreak in the West Island region of Montreal.. PubMed. 16(23). 107–10. 2 indexed citations
19.
Michel, René P., et al.. (1982). Non-Hodgkin's Lymphoma in Couples. Cancer. 50(12). 2728–2730. 9 indexed citations
20.
Carlson, George A., et al.. (1980). H‐2 associated resistance to leukaemia transplantation: Natural killing in vivo. International Journal of Cancer. 25(1). 111–122. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anthe S. Zandvliet Breakdown of academic impact, for papers by Mani Menon Breakdown of academic impact, for papers by Rayko Evstatiev Breakdown of academic impact, for papers by I Iacona Breakdown of academic impact, for papers by C. Astre Breakdown of academic impact, for papers by Henri Michel Breakdown of academic impact, for papers by Harold D. Frankl Breakdown of academic impact, for papers by Reza Khosravan Breakdown of academic impact, for papers by Thomas U. Ahearn Breakdown of academic impact, for papers by Preben Jakobsen
Rankless by CCL
2026